15.93
-0.01(-0.06%)
Currency In USD
| Previous Close | 15.94 |
| Open | 15.94 |
| Day High | 16.01 |
| Day Low | 15.14 |
| 52-Week High | 19.11 |
| 52-Week Low | 3.91 |
| Volume | 831,881 |
| Average Volume | 1.31M |
| Market Cap | 1.32B |
| PE | -5.31 |
| EPS | -3 |
| Moving Average 50 Days | 15.29 |
| Moving Average 200 Days | 11.09 |
| Change | -0.01 |
If you invested $1000 in EyePoint Pharmaceuticals, Inc. (EYPT) 10 years ago, it would be worth $455.14 as of January 14, 2026 at a share price of $15.93. Whereas If you bought $1000 worth of EyePoint Pharmaceuticals, Inc. (EYPT) shares 5 years ago, it would be worth $1,454.79 as of January 14, 2026 at a share price of $15.93.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
GlobeNewswire Inc.
Jan 07, 2026 12:00 PM GMT
– Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets – – Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 – – Phase 3 DME program first patient dosing ex
EyePoint to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Ja
EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Related Macular Degeneration
GlobeNewswire Inc.
Nov 19, 2025 12:00 PM GMT
– No changes in protocol recommended for LUGANO and LUCIA clinical trials – – Masked safety data continues to show no safety signals, consistent with previous clinical trials for DURAVYU – – On track to report topline 56-week data for LUGANO in mid-2